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Abstract 
Background: Proving that specific genes are essential for the intracellular viability of Leishmania parasites within 
macrophages remains a challenge for the identification of suitable targets for drug development. This is especially 
evident in the absence of a robust inducible expression system or functioning RNAi machinery that works in all Leish-
mania species. Currently, if a target gene of interest in extracellular parasites can only be deleted from its genomic 
locus in the presence of ectopic expression from a wild type copy, it is assumed that this gene will also be essential for 
viability in disease-promoting intracellular parasites. However, functional essentiality must be proven independently 
in both life-cycle stages for robust validation of the gene of interest as a putative target for chemical intervention.
Methods: Here, we have used plasmid shuffle methods in vivo to provide supportive genetic evidence that N-myris-
toyltransferase (NMT) is essential for Leishmania viability throughout the parasite life-cycle. Following confirmation 
of NMT essentiality in vector-transmitted promastigotes, a range of mutant parasites were used to infect mice prior 
to negative selection pressure to test the hypothesis that NMT is also essential for parasite viability in an established 
infection.
Results: Ectopically-expressed NMT was only dispensable under negative selection in the presence of another copy. 
Total parasite burdens in animals subjected to negative selection were comparable to control groups only if an addi-
tional NMT copy, not affected by the negative selection, was expressed.
Conclusions: NMT is an essential gene in all parasite life-cycle stages, confirming its role as a genetically-validated 
target for drug development.
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Background
The kinetoplast parasites, Leishmania spp., alternate 
between two distinct life-cycle stages: the flagellated and 
motile extracellular promastigotes, and the immotile 
intracellular amastigotes bearing their rudimentary fla-
gellum [1, 2]. Extracellular promastigotes develop within 
the female blood-feeding sand fly vector prior to trans-
mission to the mammalian host during a blood meal. 
Following uptake by professional phagocytes (e.g. mac-
rophages, dendritic cells), promastigotes then differenti-
ate into intracellular amastigotes. These infections result 
in a spectrum of diseases termed the leishmaniases, the 
most severe forms of which are fatal in man [3, 4]. Cur-
rently, there are only a handful of licensed drugs avail-
able to treat these infections, with most having severe 
side effects while being difficult to administer and often 
requiring patient hospitalization [5]. In addition, resist-
ance has developed in the field against some current 
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drugs and all show varying degrees of efficacy against the 
differing species of infecting Leishmania parasite [6].
Despite some advances in drug re-purposing [6, 7], 
novel drug development for the leishmaniases has not 
been a priority for the pharmaceutical industry, even 
though there is an urgent need for new approaches to the 
treatment of these deadly infections. Current efforts are 
focused on the identification of compounds that target 
and kill intracellular amastigotes [8, 9]. Two approaches 
are generally available for such screening programmes: 
phenotypic screening or screening against a known drug 
target [10, 11]. Phenotypic screening has the advan-
tage of identifying selective “cidal” compounds from 
high throughput screens of intracellular amastigotes, 
potentially identifying previously unknown/unexplored 
therapeutic pathways. A disadvantage of this approach, 
however, is that modes of action of specific compounds 
may be difficult to determine, although with the advent 
of metabolomic and chemical proteomic approaches, tar-
get deconvolution should be possible. In addition, com-
pound optimisation is difficult when the parasite target is 
unknown. These challenges are obviated in target-based 
screening, where both the target identity and its mode 
of action can be studied in detail, leading to compound 
optimisation guided by structural constraints and defini-
tion of a structure activity relationship [12, 13].
Given the potential advantages of using target-based 
screening approaches and the necessity for testing 
against intracellular amastigotes it is crucial that the tar-
get in question is essential for parasite viability within the 
intracellular environment. The target has to be a known 
gene coding for an essential protein required for parasite 
viability in the host. At present, any target gene of inter-
est is assumed to be essential for viability if it can only 
be deleted from its genomic locus when its product is 
expressed ectopically in the extracellular promastig-
ote stage of the parasite life-cycle [14, 15]. In practice, 
these gene replacements can be technically complex, 
often requiring use of more than two selectable mark-
ers, dependent on the location of the gene of interest, to 
account for the variable chromosomal ploidy of Leishma-
nia species [16]. The data generated from such geneti-
cally manipulated promastigote strains are then often 
correlated with gene function in intracellular amastig-
otes, despite the lack of phenotypic information derived 
from genuine gene knockouts generated in amastigotes. 
Generating such information is not only important for 
the robust identification of new drug targets in intracel-
lular parasites, but will also inform our understanding of 
parasite biology, ensuring, for example, that there are no 
appropriate biochemical “escape” pathways to facilitate 
amastigote survival rendering drug treatment futile and 
to predict adaptation of the parasites to inhibition.
To date, and to our knowledge, no gene essential for 
promastigote viability has also been definitively shown 
by genetic manipulation to be essential for viability in the 
Leishmania amastigote. This is principally due to the lack 
of a robust inducible expression system [17] and a func-
tioning RNAi machinery [18] that works in all Leishma-
nia species.
N-myristoyltransferase (NMT) catalyses the covalent 
attachment of a myristate moiety to the N-terminal gly-
cine of selected eukaryotic target proteins, with 60 pro-
teins predicted to be myristoylated (reviewed in [19, 20]). 
Experimentally 30 proteins were confirmed with high 
and 18 with lower confidence to be a substrate of NMT 
[21]. Gene knockout by homologous recombination 
has been used to demonstrate that NMT is an essential 
enzyme in extracellular promastigotes of Leishmania [22, 
23] as well as in both insect and mammalian extracellu-
lar stages of Trypanosoma brucei [23]. As a consequence, 
NMT is being exploited as a potential target for chemo-
therapeutic intervention across the leishmaniases, with 
high-throughput screening leading to the identification 
of first generation compounds with specificity and sensi-
tivity against Leishmania promastigotes [21, 24–26].
Plasmid shuffle is based on the concept that a plas-
mid carrying an essential gene is only dispensable in 
the presence of another functional copy of the gene or if 
necessary metabolic products are present compensating 
for the lack thereof [27]. It has already been applied to 
investigate gene function in Leishmania, but only in pro-
mastigote stages [28–31]. Methodologically, the gene of 
interest is expressed ectopically from a plasmid before it 
is deleted from its genomic locus. To direct the plasmid 
shuffle in Leishmania, this plasmid also encodes for thy-
midine kinase (TK) a negative selective marker, to force 
the death of the parasite or the loss of this plasmid upon 
negative selection with ganciclovir (GCV), a nucleoside 
analogue. TK phosphorylation occurs and the resulting 
nucleotide can be used by the parasites, interfering with 
strand elongation during DNA replication. If parasites 
die or the plasmid is only dispensable in the presence of 
another functional gene copy upon negative selection, 
then the gene can be regarded to be essential. Here, we 
have applied plasmid shuffle methodology to provide 
supportive evidence that NMT is essential in both life-
cycle stages of Leishmania parasites, thereby confirm-
ing its potential as a fully validated drug target in these 
species.
Methods
Leishmania in vitro culture
Promastigotes of L. donovani MHOM/ET/67/L28 
(LV9 strain) were grown at 26  °C in RPMI 1640 
medium (Gibco, Paisley, UK) supplemented with 20% 
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heat-inactivated FBS, 100 µM adenine, 20 mM 2-[N-mor-
pholino] ethanesulphonic acid (pH 5.5), 5 µM hemin, 
3 µM biopterin, 1 µM biotin (all Sigma-Aldrich, Irvine, 
UK), 100 U/ml penicillin and 100 μg/ml streptomycin 
(GIBCO, UK).
In vivo infections
BALB/c mice were obtained from Charles River (UK) 
and infected with 3 × 107 L. donovani stationary phase 
promastigotes, in 200  μl of RPMI 1640 (GIBCO), intra-
venously (i.v.) via the tail vein. Ganciclovir (GCV, Invivo-
gen, Toulouse, France) was dissolved in  H2O pH 12 at 10 
mg/ml and then diluted to 1.25 mg/ml in 0.1 M HEPES 
pH 7.4. Solvent control was prepared in an identical man-
ner but without the GCV. Mice were treated with 3 mg/
kg b.i.d (morning and evening (10–12 h apart) by intra-
peritoneal injection. Control mice were injected with the 
respective volume of solvent solution.
Generation of NMT‑expression plasmids
NMT was amplified from genomic DNA (forward 
primer: 5′-ACG AGA TCT ATG TCT CGC AAT CCA 
TCG AAC TC-3′; reverse primer: 5′-GCT AGA TCT 
CTA CAA CAT CAC CAA GGC AAC C-3′) and cloned 
into the BglII restriction site (restriction sites are under-
lined throughout) of pXNG4-SAT (also encoding TK and 
kindly provided by S. Beverley, Washington University, 
St Louis, USA and described elsewhere [31]) to obtain 
pXNG4-SAT-NMT. The plasmids pX-NEO-tdtom and 
pX-NEO-NMT-tdtom (tdtom denotes tandem tomato 
fluorescent protein - tdTomato) were generated by ampli-
fying LamDH intergenic region (IR) (forward primer: 
5′-ACC TCT AGA ACA TCG ATT GTG GAA GCA 
CAA AGC GCA C-3′; reverse primer: 5′-AAT TCT 
AGA CAT ATG CAA GCT GAT CCA GAG GAC GTG-
3′) and Lam NAGT IR (forward primer: 5′-TCA GGA 
TCC GAT CCA GTA GTG CCA ATA GAG-3′; reverse 
primer: 5′-ATT GCG GCC GCT CAT GTT TGA CAG 
CTT ATC ATC-3′) from pXNG4-SAT and cloning into 
the XbaI and BamHI/NotI restriction sites, respectively, 
of the pX expression vector [32]. Tdtom was generated by 
amplification from pSSU-tomato [33]; forward primer: 
5′-GAG CAT ATG GTG AGC AAG GGC GAG GAG-
3′; reverse primer: 5′-ATA GCG GCC GCA CGC GCC 
GGG CAT CGC TGC-3′) and cloned into the previously 
introduced NdeI site (reverse primer Lam NAGT IR) 
and NotI site; NMT was amplified from genomic DNA 
(forward primer: 5′-GAA CCC GGG ATG TCT CGC 
AAT CCA TCG AAC TC-3′; reverse primer: 5′-CCA 
TCT AGA CTA CAA CAT CAC CAA GGC AAC 
C-3′) and cloned into the XmaI and XbaI sites to obtain 
pX-NEO-NMT-tdtom.
Transfected Leishmania lines
For generation of conditional double NMT allele replace-
ment mutants, L. donovani  NMTHYG/+ promastigotes 
[22] were transfected with pXNG4-SAT-NMT. Replace-
ment of the second NMT allele was achieved by targeted 
gene replacement as described [22]. One confirmed 
genomic homozygous NMT knockout carrying the 
pXNG4-SAT-NMT plasmid line was then used for trans-
fection with pX-NEO-tdtom or pX-NEO-NMT-tdtom.
Transfections were performed sequentially with 5 μg 
purified DNA by nucleofection (using the Human T Cell 
Nucleofector Kit, Lonza, Basel, Switzerland) of 2 × 107 
mid-log phase promastigotes. Mutants were selected on 
RPMI medium/1% agar plates with respective antibiot-
ics (32 μg/ml hygromycin B; 40 μg/ml G418; 80 μg/ml 
puromycin; 100 μg/ml nourseothricin). PCR screening to 
confirm the correct targeting of the 2nd allele was per-
formed with the following forward primers: PACint (5′-
ACC TGG TGC ATG ACC CGC AAG-3′), HYG (5′-CCT 
GAA CTC ACC GCG ACG TC-3′) and LdNMT (5′-CTA 
TGC CCA CCG AGC TAC ATC C-3′) together with the 
reverse primer: Syntaxin Rev (5′-GCC AGC TGC GTC 
AAA CGC AT-3′).
Intracellular in vitro analysis
Bone marrow was extracted from 6–8 week-old female 
BALB/c mice and differentiated to macrophages with 
L929 conditioned medium. Alternatively, THP-1 
cells were transformed to macrophages with phor-
bol 12-myristate 13-acetate (PMA) or retinoic acid as 
described in [34] or [35], respectively. Macrophages were 
infected with a MOI of 10 with stationary promastigotes. 
Upon transformation to amastigotes, in our hands it took 
72 h, the cells were either treated with 50 μg/ml GCV or 
solvent. At the appropriate time points, PMA stimulated 
cell were lifted of the well bottom upon two washes with 
PBS with a cell scraper and then collected as described 
in [35]. Retinoic acid-stimulated cells were harvested as 
described in [35]. Cells were then subjected to flow cyto-
metric or microscopic analysis.
Flow cytometry
GFP and tdtom expression was assessed in live promas-
tigotes suspended in PBS by flow cytometry. Cells were 
analysed on a DAKO CyAn ADP analyser (DakoCytoma-
tion, Ely, UK) and data were analysed with FlowJo v10.0.6 
(TreeStar Inc., Ashland, OR, USA).
Parasite burdens
Splenic parasite burdens were determined by limiting 
dilution assay as described [36]. Spleens were dounce-
homogenized and then plated out as described, in the 
presence/absence of the following concentrations of 
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selection antibiotics as appropriate: hygromycin (32 μg/
ml); nourseothricin (100 μg/ml); puromycin (80 μg/ml); 
G418 (40 μg/ml).
Statistics
Analysis of statistically significant differences between 
groups were performed by Mann–Whitney test using 
GraphPad Prism v8 (GraphPad Software Inc., San Diego, 
CA, USA)
Results
Generation and characterisation of conditional genomic 
NMT allele deletions
NMT had previously been shown to be essential for the 
viability of L. donovani promastigotes [22]. In the pre-
sent study, in order for us to replace both genomic NMT 
alleles in these experiments, it was necessary to express 
an NMT gene copy at an ectopic locus, in this case, from 
one of two or two distinct plasmids expressing different 
reporters GFP or tdTom. The strategy for generation and 
use of the resulting parasite lines in these new plasmid 
shuffle experiments is shown in Fig.  1. Flow cytometry 
was used to monitor the fate of either plasmid by detect-
ing GFP or tdtom expression. This allowed us to deter-
mine whether NMT is an essential or dispensable gene 
for parasite viability. The open reading frame of L. dono-
vani NMT (ORF) was cloned into the plasmid pXNG4Sat 
(hereafter called NMT-TK; coding for GFP, TK and the 
selection marker, S-streptothricin acetyltransferase (SAT; 
[31]). This plasmid was transfected into L. donovani het-
erozygous for NMT, NMT HYG/+ [22]. The ectopic expres-
sion of NMT from the plasmid made it possible to replace 
the second genomic NMT allele (Fig.  2a-d). The result-
ing parasite line, LV9 ΔNMT HYG/PAC [NMT-TK], was 
then transfected with a second plasmid, either encod-
ing tdTomato and neomycin phosphotransferase (NEO) 
alone (hereafter called tdtom) or tdTomato and NEO plus 
LdNMT (hereafter called NMT-tdtom). The second plas-
mid was engineered so that the tdTomato was under the 
same regulatory control as GFP in the NMT-TK plasmid. 
The histograms depicting the fluorescent characteristics 
of the parasite lines generated are also shown on the right 
in Fig.  1. All of these parasite lines moderately overex-
pressed NMT compared to wild type (wt) levels (Addi-
tional file 1: Figure S1) but below the lethal ~5-fold limit 
as reported for L. major [23]. Table  1 summarises the 
three plasmids and their characteristics used here.
Qualitative and quantitative in vitro analysis
First, it was necessary to establish that the plasmid shuf-
fle approach works in the extracellular life-cycle stage, in 
which NMT has already been shown to be essential for 
viability [23] and to monitor the effect of GCV on these 
promastigotes. The hypothesis was that upon negative 
selection, the NMT-TK plasmid could only be lost in the 
presence of another expressed NMT copy present on a 
second plasmid. In the absence of this second NMT copy, 
we expected the parasites to die or to maintain the NMT-
TK plasmid.
No effects were observed following GCV treatment of 
L. donovani NMT single knockout (KO) promastigotes 
transfected with the tdtom plasmid (Fig.  3a). However, 
the absence of the antibiotics hygromycin and G418 in 
the GCV-treated samples led to the loss of this plas-
mid in 14% of the parasite population (Fig.  3a). Double 
NMT KO promastigotes transfected with NMT-TK did 
not show altered fluorescent characteristics even upon 
GCV treatment for 5 passages (~50 generations) and in 
the absence of nourseothricin to select for this plasmid. 
The main population remained GFP-positive as in the 
untreated parasites. However, the lower GFP fluorescent-
positive (dim) population increased from 10.6% to 30.2% 
(Additional file  2: Figure S2) gate spanning ~1 log scale 
across the GFP dim population shown in Fig. 1, this gate 
is slightly shifted along the X-axis to include the majority 
of the GFP-dim parasites), similar to that described ear-
lier for essential genes [28, 31] and attributed to either a 
low copy number of the pXNG4 plasmid [31] or reduced 
GFP expression, possibly due to cellular stress [28].
Leishmania donovani double NMT KO promastig-
otes, only expressing NMT from the NMT-TK plasmid, 
did not lose this plasmid, even after ~50 generations in 
the presence of 50 μg/ml GCV (Fig.  3b). The majority 
of these parasites were still GFP/tdtom-positive, ~45%, 
or purely GFP-positive, ~30%, with again a dim GFP-
positive population (based on gates shown in Additional 
file 2: Figure S2), ~30%, of which ~14% were also tdtom-
positive (Fig.  3b). A similar distribution was recorded 
after 2 passages (~15 generations) with GCV. There was 
no apparent change between the control parasites main-
tained for 2 or 5 passages in the appropriate antibiotics to 
select for the plasmids (Fig. 3b) 89.1% and 92.2% double 
positive, respectively.
Leishmania donovani promastigotes with double NMT 
KOs expressing NMT from the second plasmid, NMT-
tdtom, did lose the NMT-TK plasmid over time when 
cultured in the presence of 50 μg/ml GCV, as expected. 
This plasmid was completely lost after ~50 genera-
tions with the parasites remaining solely tdtom-positive 
(Fig.  3c). In comparison, the control parasites main-
tained in the appropriate selecting antibiotics did not dif-
fer from the starting population (Fig. 3c). Table 2 shows 
the median fluorescence intensity (MFI) values of the 
GFP fluorescence for the GFP dim populations. Results 
indicate a clear and consistent skew towards higher GFP 
fluorescence in the groups where the NMT-TK plasmid is 
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present in the GCV-untreated groups and in the double 
NMT KOs where NMT-TK had to be maintained. These 
data confirm that a copy of the NMT gene is essential for 
promastigote viability in a direct in vitro assay. The tar-
geted loss of NMT-TK upon GCV treatment in parasites 
carrying an additional copy on NMT confirms that the 
GCV selection is functional.
Intracellular in vitro analysis
Next, we wanted to apply the plasmid shuffle method 
to test whether NMT is also essential in the intracel-
lular life-cycle stage of Leishmania. At first an in vitro 
approach was pursued, with two sources of phagocytes 
used for infection with the promastigote mutant lines 
described above: murine bone marrow-derived mac-
rophages and PMA [34] and retinoic acid [35] stimulated 
human THP-1 cells. Upon transformation of promastig-
otes to amastigotes inside these cells, macrophages were 
treated with GCV or solvent. However, during this tran-
sition, it was noted that the GFP fluorescent intensity had 
dropped considerably when compared to the starting 
promastigotes, such that it was not possible to discrimi-
nate between single GFP-positive cells, dim GFP-positive 
cells or dim GFP/tdtom-positive cells (data not shown). 
Fig. 1 Overview of plasmid shuffle experimental procedure. Generation of conditional L. donovani NMT null mutants to demonstrate NMT 
essentiality by plasmid shuffle. Heterozygous NMTHYG/+ promastigotes (1) were episomally transfected with pXNG4-NMT-TK carrying GFP and TK (2), 
before targeting the 2nd NMT allele for replacement with PAC, creating NMTPAC/HYG (3). Individual clones were then transfected with an episomal 
plasmid coding for tdtom only or for NMT and tdtom (NMT-tdtom; 4). Ectopic expression of NMT by only one (pXNG4-NMT-TK) of the two plasmids 
(right hand side scenario) or both (left hand side scenario) will allow genetic validation of its essentiality by negative selection with ganciclovir 
(GCV, 5). If NMT is an essential gene, mutants will grow, after several passages of negative selection that are only tdtom+, when parasites were 
transfected with pXNG4-NMT-TK/NMT-tdtom, or GFP+ and tdtom+, when transfected with pXNG4-NMT-TK/tdtom, respectively. The latter may 
not grow but rather die due to the negative selection. If NMT is non-essential for viability, retention of plasmids during cytokinesis will be subject 
to a random distribution and tdtom+ and/or GFP+ mutants could arise in both conditional complementation settings or the plasmids will not 
be retained at all. Histograms shown on the right in 1–4 depict representative fluorescent properties for GFP and tdtom of the heterozygous 
NMTHYG/+ parasites (1- starting population) and mutants generated by episomal plasmid transfection (2–4, grey filled curve, no fill shows starting 
population). Abbreviations: NMT, N-myristoyltransferase; SAT, streptothricin acetyltransferase; HYG, hygromycin phosphotransferase; PAC, puromycin 
N-acetyltransferase; NEO, neomycin phosphotransferase; GFP, green fluorescent protein; tdtom, tandem tomato fluorescent protein; TK, thymidine 
kinase from Herpes simplex virus; ess, essential
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It was concluded from this observation that the differen-
tiated amastigotes did not proliferate at a sufficient rate 
for robust detection in either of these cellular systems 
and the doublings needed for an efficient loss of the plas-
mid in a single round of in vitro macrophage infection are 
not achievable. Hence, in vivo whole animal experiments 
were initiated as an alternative approach.
Qualitative in vivo analysis
To investigate to what extent and under what circum-
stances the NMT-TK plasmid could be lost in vivo, 
groups of BALB/c mice were infected with stationary 
phase L. donovani promastigotes of the different trans-
genic lines as shown in Fig.  4. Mice were then treated 
twice daily with GCV starting at one week post-infection 
in order to make sure promastigotes have transformed 
into amastigotes and the infection had time to establish 
itself; Additional file  3: Figure S3 shows flow cytometry 
plots of the parasites used in these experiments. After 
a further 4 weeks, mice were sacrificed, and the spleens 
removed to determine the level of parasitaemia by lim-
iting dilution assay (parasites are not cleared from the 
Fig. 2 PCR analysis of NMT complemented double replacement HYG/PAC parasites. a Diagram of NMT locus and targeted single alleles containing 
replacement by either the HYG or PAC genes. 5′flank and 3′flank boxes represent NMT flanking regions used for gene targeting. 5′DHFR and 3′DHFR 
boxes represent 5′ and 3′ dihydrofolate reductase flanking regions. Arrows show positions of primers used in PCR analysis of clones in b–d. Lane 
1: LV9 NMT HYG/PAC [NMT-TK]; Lane 2: LV9 NMT HYG/PAC [NMT-TK] clone 12; Lane 3: LV9 NMT HYG/PAC [NMT-TK] clone 18; Lane 4: LV9 NMT HYG/+; Lane 5: 
LV9 wild type; Lane 6: no DNA control. b PAC integration, expected band 2513 bp. c HYG integration, expected band 3488 bp. d Genomic NMT, 
expected band 2097 bp. Allelic NMT was only replaced completely for clone 12 while clone 18 retained the gene. Clone 12 was used to generate 
LV9 NMT HYG/PAC [NMT-TK][NMT-tdtom] or LV9 NMT HYG/PAC [NMT-TK][tdtom]
Table 1 Overview of plasmids used and their characteristics
Abbreviation used in 
manuscript
Fluorescence Antibiotic gene N-myristoyl-
transferase present?
Thymidine kinase 
present?
Antibiotic used for selection
NMT-TK GFP Neomycin phospho-transferase Yes Yes G418
NMT-tdtom tdtom Streptothricin acetyl-transferase Yes No Nourseothricin
tdtom tdtom Streptothricin acetyl-transferase No No Nourseothricin
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Fig. 3 Promastigote flow cytometric assay. a Flow cytometric characteristics of single and double knockouts only transfected with a single plasmid 
in presence and absence of ganciclovir (GCV). b In the NMT double knockout parasites the plasmid pXNG4-SAT-NMT could not be lost in the 
absence of a second ectopic NMT allele. c The plasmid pXNG4-SAT-NMT was lost in the NMT double knockout parasites over several passages in the 
presence of a second ectopic NMT allele. Mutants were kept for 2 and/or 5 passages in medium containing GCV or in medium containing either 
hygromycin and G418 or hygromycin, puromycin and nourseothricin, respectively, at which point they where analyzed by flow cytometry. NMTHYG/+ 
[tdtom] = LV9 NMTHYG/+ [ tdtom] cl. 13; NMT HYG/PAC [NMT-TK] = LV9 NMT HYG/PAC [NMT-TK] cl. 12
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spleen over this time period; [37]). The extent to which 
parasites were resistant to the different combinations 
of antibiotics, and its correlation with retention of spe-
cific plasmids was also measured. Table  3 summarises 
the mutant lines of L. donovani used for the qualitative 
and quantitative plasmid retention experiments and the 
applied selection conditions. To further investigate the 
dynamics of plasmid retention, the same samples were 
also re-differentiated into promastigotes, grown with 
the respective antibiotics for single or double NMT KO 
s, and subsequently analysed by flow cytometry (Fig. 5). 
Each column represents a different mutant line and each 
row represents for which plasmid(s) was selected for by 
respective antibiotics, no plasmid i.e. total population, 
isolated from infected mice that were GCV-untreated 
(-) or GCV-treated (+) (Fig. 5, rows 1 and 2). In order to 
gain more insight how the population was composed, the 
parasite samples were subjected to the respective antibi-
otics to select for either plasmid or both together (Fig. 5, 
rows 3–8).
The predominant population of splenic single NMT 
KOs had lost the NMT-TK plasmid (Fig. 5, column C, 
row 1 (C1 and C2) and Additional file  4: Figure S4), 
Table 2 Median fluorescence intensity (MFI) values for the GFP 
signal of the GFP dim population (quadrant 1 is top left and 
quadrant 4 bottom left)
Abbreviation: na, not applicable
Genomic setting of Leishmania (mutant) 
line
Quadrant MFI of GFP 
signal
− GCV + GCV
wt Q1 na na
Q4 4.0 na
NMT HYG/+ [tdtom] Q1 3.8 3.3
Q4 na 3.9
NMT HYG/PAC [NMT-TK] Q1 na na
Q4 6.8 7.0
NMT HYG/PAC [NMT-TK][tdtom] cl. 3 Q1 7.0 7.1
Q4 na 7.4
NMT HYG/PAC [NMT-TK][tdtom] cl. 7 Q1 8.2 7.2
Q4 na 7.5
NMT HYG/PAC [NMT-TK][NMT-tdtom] cl. 3 Q1 7.0 2.7
Q4 na na
NMT HYG/PAC [NMT-TK][NMT-tdtom] cl. 4 Q1 7.3 3.7
Q4 na na
Fig. 4 Flow chart describing the in vivo experimental plan. Day 35 spleens were harvested and a limiting dilution assay (LDA) set-up. Condition 1: 
the medium used in the LDA only contained antibiotics selecting for single NMT or double NMT knockouts, depending on the mutants initially 
injected, in order to determine the total parasite burden. Conditions 2–4 were set up to determine the individual parasite burden, i.e. which plasmid 
are the parasite still carrying: Condition 2: LDA medium contained also nourseothricin to select for the NMT-TK plasmid. Condition 3: LDA medium 
contained also G418 to select for the NMT-tdtom or the tdtom plasmid. Condition 4: the medium contained also nourseothricin and G418 to select 
either for the NMT-TK and NMT-tdtom plasmid or the NMT-TK and tdtom plasmid
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even in the untreated group. However, we were able to 
recover a small subset of parasites were this plasmid 
was still present, both treated or untreated as identi-
fied under appropriate selection with hygromycin and 
nourseothricin (Fig. 5, C3, C4). The NMT-TK plasmid, 
however, was retained in double NMT KOs under all 
selection conditions (Fig.  5, D1–D4; Additional file  5: 
Figure S5).
Double NMT KOs also possessing ectopic NMT alleles 
encoded by the NMT-TK or the NMT-tdtom plasmid 
were isolated from spleens of BALB/c mice. Both the 
GCV-treated and GCV-untreated parasites were exclu-
sively  tdtom+ (Fig.  5, A1, A2; Additional file  6: Figure 
S6), consistent with possession of only a single NMT 
allele. It was still possible to identify parasites as a  GFP+ 
or as double positive  (GFP+/tdtom+) population when 
selected for the NMT-TK plasmid (Fig.  5, A3, A4). No 
difference was observed in the qualitative analysis when 
these mutants were selected for the NMT-tdtom plasmid 
(Fig. 5, A5, A6). Both GCV-treated and GCV-untreated 
parasites resulted in a  tdtom+ population, reflecting the 
result obtained in the majority of the population (Fig. 5, 
A1, A2). In GCV-untreated parasites, selection for NMT-
TK and NMT-tdtom plasmids (Fig.  5, A7) resulted in 
tdtom+ and  GFP+ populations, as in the original para-
sites injected. However, when we selected for parasites 
still carrying both plasmids, there were almost no dou-
ble positive parasites left in the population extracted 
from mice treated with GCV (Fig.  5, A8). This result is 
in agreement with previous results (Fig. 5, C1–C4), con-
firming that the NMT-TK plasmid was lost while the 
NMT-tdtom plasmid was almost exclusively retained (i.e. 
Fig. 5, A2 and A6).
Double NMT KO parasites only possessing an ectopic 
NMT allele, encoded by the NMT-TK plasmid, when 
isolated from the spleens of GCV-treated and GCV-
untreated BALB/c mice, were  GFP+ or GFP+/tdtom+ in 
both groups (Fig. 5, B1 and B2; Additional file 7: Figure 
S7). Selecting for the NMT-TK plasmid (Fig.  5, B3, B4) 
in parasites isolated from untreated mice resulted in an 
almost exclusive  GFP+ population. Similarly, selection for 
the NMT-TK plasmid in the GCV-treated group resulted 
in  GFP+ (46%) and  GFP+/tdtom+ (37%).
Selecting for the tdtom plasmid not encoding NMT in 
the GCV-untreated group (Fig. 5 B5) resulted in a mainly 
double positive (90%  GFP+/tdtom+) population as in the 
original injected population. However, almost no para-
sites could be detected in the GCV-treated group and the 
few that were detected were also double positive (Fig. 5 
B6). The double negative population was comprised of 
splenic cells as confirmed by microscopy.
In GCV-treated and GCV-untreated parasites, selec-
tion for the NMT-TK and tdtom plasmid (Fig. 5 B7, B8) 
resulted in  GFP+/tdtom+ populations identical to the 
profile of the originally injected parasites.
In summary, the NMT-TK plasmid does not need to 
be maintained in the presence of another endogenous 
or ectopic gene copy of NMT even in the absence of 
negative drug pressure (Fig. 5, A1 and C1). In contrast, 
the NMT-TK plasmid is retained in the absence of 
another NMT gene (Fig. 5, B1 and D1).
The average median fluorescence intensity (MFI) val-
ues of the GFP fluorescence in the tdtom gate for the 4–5 
animals are shown in Table 4. For the wt population the 
median MFI for GFP was determined by drawing a gate 
around the population and it was 2 and 2.1 in the GCV-
untreated and GCV-treated population, respectively. 
The GFP MFI in the tdtom+ gate for double NMT KO 
[NMT-TK][tdtom] was 5.6 and double NMT KO [NMT-
TK][NMT-tdtom] was 4.8 on the day of the injection. In 
the double NMT KO parasites possessing ectopic NMT 
alleles encoded by the NMT-TK or the NMT-tdtom 
plasmid in the GCV-treated groups the GFP MFI in the 
tdtom+ gate was very low (2.6 and 2.8, respectively) 
when only selected for the double KO and the red plas-
mid, respectively. Similarly the MFI values in the tdtom+ 
gate in the GCV-untreated groups, possessing only 
ectopic NMT alleles encoded by the NMT-TK or the 
NMT-tdtom plasmid and selection was only performed 
for the double KO or the red plasmid, were also very 
low (3.2 and 3.0, respectively). This confirms that these 
populations mainly or only possess the tdtom plasmid. 
Table 3 Leishmania donovani mutant lines used for the qualitative and quantitative plasmid retention experiments in Figs. 5, 6, 7 and 
the applied selection conditions
Abbreviation: na, not applicable
Leishmania mutant line Antibiotic used to select for specific plasmid(s)
nourseothricin G418 nourseothricin/G418
LV9 NMTHYG/+ [NMT-TK] NMT-TK na na
LV9 NMT HYG/PAC [NMT–TK] NMT-TK na na
LV9 NMT HYG/PAC [NMT–TK] [tdtom] NMT-TK tdtom NMT-TK; tdtom
LV9 NMT HYG/PAC [NMT–TK] [NMT-tdtom] NMT-TK NMT-tdtom NMT-TK; NMT-tdtom
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Fig. 5 NMT is essential in L. donovani amastigotes: qualitative analysis. Representative flow cytometry plots (plotted y-axis: tdtom, x-axis: GFP) from 
parasites obtained from spleens of BALB/c mice treated for 28 days with 3 mg/kg per day− b.i.d with ganciclovir (+; GCV) or with solvent (−). The 
predominant population was identified for each condition (single or double knockout, transfected with NMT-TK plus either the NMT-tdtom or the 
tdtom plasmid) by selecting for no plasmid (medium only, wt; hygromycin NMTHYG/+ [NMT-TK]; all others hygromycin and puromycin) in the top 
two rows; for NMT-TK plasmid (as before plus nourseothricin; rows 3 and 4); for NMT-tdtom or tdtom plasmid (hygromycin, puromycin and G418; 
rows 5 and 6); for NMT-TK/NMT-tdtom or NMT-TK/tdtom plasmid (hygromycin, puromycin, nourseothricin and G418; rows 7 and 8). See Additional 
files 4, 5, 6, 7, 8: Figures S4–S8 for flow cytometry plots for each mouse. Flow cytometric analysis was performed 14 days after spleens were removed 
and parasites grew out from cell suspension
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In all other cases, the GFP MFI in the tdtom+ gate was 
between 4.0–4.4 as there was also a contribution of the 
NMT-TK plasmid with its GFP dim population.
In the double NMT KO parasites only possessing an 
ectopic NMT allele, encoded by the NMT-TK plasmid 
there was a clear skew towards higher MFI values (the 
lowest was 3.6 and the highest was 6.2). The lower val-
ues were only observed when only very few events were 
recorded in the tdtom+ gate. This confirms that there is 
always a contribution of the GFP dim population in the 
tdtom+ gate, highlighting the fact that the parasites need 
to maintain the NMT-TK plasmid.
Quantitative in vivo analysis
The total burden of parasites in the spleen after 35 days 
of infection and 28 days of treatment was determined by 
limiting dilution assay (Fig.  6). There was no difference 
observed in the total splenic numbers of L. donovani wt 
parasites in solvent control or GCV-treated mice. No 
significant differences were observed in mice infected 
with single NMT KOs and expressing NMT from an 
ectopic locus nor if NMT was expressed solely ectopi-
cally from both plasmids LV9 NMT+/HYG [NMT-TK] 
and LV9 ΔNMT [NMT-TK] [NMT-tdtom], although the 
parasite burdens were slightly less in the GCV-treated 
animals. However, parasite burdens were significantly 
reduced upon treatment with GCV in mice infected with 
NMT double KO parasites and with NMT only encoded 
by the NMT-TK plasmid (LV9 ΔNMT [NMT-TK] and 
LV9 ΔNMT  [NMT-TK][tdtom]; Mann–Whitney U-test: 
U = 0, P = 0.0079).
All mutant lines resulted in a lower splenic parasite 
burden compared to the wt parasites. It was further 
noted that the parasite burdens were markedly reduced 
(Mann–Whitney U-test: U = 0, P = 0.0079) when NMT 
was only expressed from the NMT-TK plasmid as com-
pared to the mutants in which NMT was also expressed 
from one genomic allele or from the NMT-tdtom 
Table 4 Average median fluorescence intensity (MFI) values of 
the GFP signal in the tdtom+ gate
a Antibiotic combinations used for group selection (H – Hygromycin, P – 
Puromycin, S – Nourseothricin, N – G418)
b MFI values of parasites at day of injection
Abbreviation: na, not applicable
Selection 
 conditiona
GCV NMT HYG/PAC
[NMT-TK] 
[tdtom]
NMT HYG/PAC[NMT-TK] 
[NMT-tdtom]
wt
Entryb 5.6 4.8
HP − 3.6 3.2
+ 4.7 2.6
HPS − 3.6 4.0
+ 4.8 4.4
HPN − 4.3 3.0
+ 5.3 2.8
HPNS − 5.0 4.4
+ 6.2 4.0
na − 2.0
+ 2.1
Fig. 6 Quantitative analysis of total parasite burden. Parasite burden 
in spleen of BALB/c mice, 5 mice per group, after infection of spleen 
with LV9 wt, LV9 NMT+/HYG [NMT-TK], LV9 ΔNMT [NMT-TK], LV9 ΔNMT 
[NMT-TK][NMT-tdtom] or LV9 ΔNMT [NMT-TK][tdtom] and treating 
with Ganciclovir (3 mg/kg per day; open symbols) or with diluent/
solvent (filled symbols) for 28 days b.i.d. There was no difference in 
total parasite burden between treated and untreated wt parasites or 
when the second allele of NMT was present or NMT was ectopically 
expressed from a plasmid. However, the total parasite burden 
significantly dropped in mice upon treatment with GCV if parasites 
were double NMT KOs or it was not ectopically expressed from a 
plasmid. In the GCV-treated group of wt, LV9 NMT+/HYG [NMT-TK] and 
LV9 ΔNMT [NMT-TK][NMT-tdtom], one animal had to be sacrificed for 
ethical reasons. Statistics: Mann–Whitney test *P < 0.5, **P < 0.05
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plasmid, indicating that the correct regulation of NMT 
expression is important in this context. The burdens 
upon GCV treatment were comparable when NMT 
was only expressed from the NMT-TK plasmid (Fig.  6), 
although the burdens were lower in the solvent-treated 
mice when the parasites also carried the tdtom plasmid 
(Fig. 6).
The splenic parasite burden in the GCV untreated 
groups varied (Fig. 6). This suggested the over-expression 
of NMT and the regulation of its expression had an effect 
on the infectivity and/or the doubling-time of the para-
sites. Of note, this could be an effect due to the genetic 
manipulation in general and/or the general loss of infec-
tivity observed when parasites are cultured axenically, a 
process particularly evident in L. donovani [38, 39]. Due 
to technical reasons, mutant lines were not passaged 
through mice as it was assumed that without selection 
for the plasmids by the respective antibiotics in vivo, dis-
pensable plasmids would be lost rapidly; this assumption 
was later confirmed (see Fig. 5, A1, B1, C1 and D1).
In the surviving total splenic parasite population, it 
was further assessed as to what extent the plasmids were 
retained. This was also done by a limiting dilution assay 
but in the presence of the respective antibiotics (Fig. 7). 
Significantly lower burdens were observed upon GCV 
treatment compared to solvent treatment (Mann–Whit-
ney U-test: U = 0, P = 0.0159 and Mann–Whitney U-test: 
U = 0, P = 0.0079), when subsequently selected for the 
NMT-TK plasmid. There were almost no parasites pre-
sent in the spleen still carrying this NMT-TK plasmid 
Fig. 7 Quantitative analysis of the individual parasite burden and thus inferred plasmid retention. Proportion of parasite total burden in the 
spleen of BALB/c mice infected with LV9 NMT+/HYG [NMT-TK], LV9 ΔNMT [NMT-TK], LV9 ΔNMT [NMT-TK][NMT-tdtom] or LV9 ΔNMT [NMT-TK][tdtom] 
are selected for by limiting dilution assay with the appropriate drugs. a Selection for the presence of plasmid coding for NMT, TK and GFP. Upon 
treatment with GCV for 28 days (3 mg/kg per day− b.i.d; open symbols), parasites have almost entirely lost the plasmid encoding for TK, NMT, GFP. b 
Selection for the presence of the plasmid coding for NMT and tdtom or tdtom alone. Upon GCV treatment, there were ~100 times more parasites 
present if an additional NMT allele/gene was encoded. No significant difference between the untreated and treated group was observed. However, 
if no additional NMT allele/gene was present, parasites, survival was less (untreated group) and upon GCV treatment, those parasites were not 
detectable. c Selection for the presence of parasites positive for both plasmids, i.e. encoding NMT, TK & GFP and NMT & tdtom or only tdtom. Upon 
GCV treatment, only a few parasites were present in the spleen encoding for both plasmids. There were more parasites in the spleen in the group 
not encoding for a second NMT gene carrying both plasmids. However this number was not significant (Mann–Whitney test *P < 0.5, **P < 0.05)
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(Fig. 7a). This was the case for all mutant lines in which 
NMT was present either as a genomic allele or expressed 
from an ectopic locus. On the other hand, a significant 
difference (Mann–Whitney U-test: U = 0, P = 0.0079) 
was observed in the splenic parasite burdens in mice 
upon treatment with GCV compared to the solvent-
treated and subsequently selected for the tdtom plas-
mid (Fig.  7b). As expected, if NMT is essential and no 
genomic NMT allele is present, no significant difference 
in the parasite burden was observed when selected for 
the NMT-tdtom plasmid in the GCV or solvent-treated 
group (Fig. 7b), indicating the necessity for the presence 
of NMT for parasite viability.
In agreement with the hypothesis that NMT is an 
essential gene in amastigotes, a significant difference 
(Mann–Whitney U-test: U = 0, P = 0.0159) in the para-
site burden was observed upon treatment with GCV 
and the subsequent selection for the NMT-TK and the 
NMT-tdtom plasmids as compared to the solvent group 
(Fig.  7c). This was due to loss of the NMT-TK plasmid. 
However, no difference was observed in the parasite bur-
dens in mice treated with GCV or the solvent and subse-
quent selection for the NMT-TK and the tdtom plasmid 
(Fig. 7c), indicating that there is no selection in mice for 
the plasmid encoding only tdtom. This is in agreement 
with the qualitative data (Fig. 5, B1 and B2) where it was 
shown that the predominant population in the solvent-
treated group had mostly lost the plasmid coding only for 
tdtom, while in the GCV-treated group the predominant 
population was only carrying the NMT-TK plasmid.
Discussion
Determining the essentiality of a gene in Leishmania 
species, especially in intracellular amastigotes, is chal-
lenging. At present, an absolute requirement for para-
site viability is assumed when it is only possible to fully 
delete a target gene of interest from its genomic locus 
when an ectopically expressed additional gene copy is 
present. This type of analysis has been exclusively per-
formed in extracellular promastigote stages of the para-
site life-cycle to date, with the information generated 
then correlated with similar function in intracellular 
amastigotes. Plasmid shuffle [31] provides an alterna-
tive approach for the positive discrimination of essen-
tial genes as it involves not only the deletion of the gene 
of interest from its genomic locus in the presence of an 
ectopic copy, but testing of whether this ectopic copy is 
dispensable upon negative selection [28–30]. Morales 
et  al. [30] employed this approach to demonstrate an 
absolute requirement for the co-chaperone STI1 in 
parasite viability and its essential residues necessary 
for phosphorylation, while Dacher et al. [28] used simi-
lar methods to show that activity of the protein kinase 
LmaMPK4 is also required. However, both studies were 
carried out using extracellular promastigotes.
TK-expressing amastigotes of both L. donovani and 
L. major have already been described elsewhere. Muy-
ombwe et  al. [40] infected murine and human mac-
rophages with L. major promastigotes expressing a TK 
plasmid and, following differentiation into amastigotes 
and subsequent treatment with GCV, showed decreased 
intracellular infection levels over time. Similarly, Ghedin 
et  al. [41] expressed TK under the control of the A2 
gene in L. donovani promastigotes, prior to infection of 
murine primary macrophages. Subsequent GCV treat-
ment decreased infection levels substantially.
Here, we wanted to take the plasmid shuffle technique 
a step further and use it to prove the essentiality of a 
potential drug target gene in intracellular amastigotes. 
Using this approach, we first confirmed our previous 
observations that NMT is an essential gene in promas-
tigotes in two Leishmania species [22, 23]. These experi-
ments also demonstrated that the plasmid shuffle system 
was reproducible in our hands. We observed that during 
negative selection with GCV, a replicating population of 
parasites was necessary. Our data indicate that the TK-
encoding plasmid is not actively lost but rather decreases 
in abundance through unequal division/propagation dur-
ing mitosis and cytokinesis. Parasites without this plas-
mid then have a growth advantage and will outgrow the 
population which still contains the plasmid; as a result, 
3–5 passages (i.e. ~25–50 generations) are needed to 
lose the plasmid in vitro. This also explains why we were 
unable to perform these experiments with different mac-
rophage populations using the transgenic L. donovani 
parasites, which did not replicate fast enough intracel-
lularly for detection in vitro. Other parasite species such 
as Leishmania mexicana or L. amazonesis could be more 
amenable to use of this in vitro strategy, as these strains 
replicate more rapidly in macrophage cell lines.
However, promastigotes expressing NMT only from the 
NMT-TK plasmid propagated even under GCV selec-
tion. This might be due to the inactivation of TK under 
negative selection as has been described in T. brucei, due 
to a single point mutation or a frame shift [42]. Although 
we cannot exclude that the GCV negative selection lead 
to TK inactivation here, it has been reported in previous 
Leishmania promastigote plasmid shuffle experiments 
that negative selection did not cause a similar TK muta-
tion. Instead GCV was tolerated by the parasites [28]. 
Taken together, this indicates that Leishmania promas-
tigotes can deal with GCV stress much better than T. 
brucei.
Given our focus on L. donovani, we therefore decided 
to work in vivo and chose a susceptible mouse strain 
that develops persistent splenic infection with a constant 
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increase in splenic parasite burden over at least 112 days 
[37]. Mice were infected intravenously with promastig-
otes, with GCV treatment or control injections com-
mencing 7 days later, after promastigote transformation 
and establishment of an amastigote infection. After 4 
weeks of treatment, spleen parasite burdens and com-
positions were determined, setting up limiting dilution 
assays with the respective antibiotics to select for para-
sites still carrying both or either plasmid. The quantita-
tive analysis revealed that NMT is essential for viability 
in intracellular amastigotes of L. donovani, hence con-
firming the validity of this enzyme as a target for drug 
development. The data also showed that a plasmid cod-
ing for an essential gene and TK can only be lost in vitro 
when a functional copy of the essential gene is present, 
even in the presence of GCV. In vivo, on the other hand, 
it appears that these parasites die either by necrosis or 
immune clearance. However, clearance of all parasites 
from spleens was not complete as promastigotes for flow 
cytometric analysis grew out in 8 out of 9 animals if NMT 
was only encoded by an episome. This highlights the fact 
that some parasites might undergo quiescence [43] upon 
negative selection pressure and replication of parasites 
resumes once negative selection pressure is removed. 
This circumstance could lead to recrudescence in a 
chemical intervention. It is also possible that the treat-
ment has just not been long enough as no promastigotes 
grew out of the spleen for one animal indicating complete 
clearance is possible. The qualitative analysis appears to 
indicate that the GCV treatment in vivo is not necessary, 
as there is no apparent difference between GCV-treated 
and untreated. However, these discrepancies come from 
the fact that the flow cytometric analysis was done some 
time after the parasites have been freed from the spleens, 
thus what was present at the end of the GCV treatment 
was then again amplified. There was a 10-fold difference 
in the quantitative analysis in the amount of parasites 
present in the spleen between the treated and untreated 
group if NMT is only encoded on a single chromosome 
or plasmid. Quantitative PCR on the day of parasite iso-
lation could be more precise in determining the plasmid 
levels present in the parasite population. However, the 
NMT-TK plasmid appears to have an intrinsic toxicity as 
it is not maintained over the period of the experiments in 
the GCV-untreated single NMT KOs group or in the dou-
ble NMT KOs if the NMT-tdtom plasmid is present. In 
contrast, in the NMT KOs the NMT-TK plasmid is main-
tained if it is the sole source for NMT expression. Possi-
bly the use of almost identical plasmids only differing by 
the fluorescent marker and encoding for an inactivated 
TK will reduce the inherent negative selection pressure 
due to varying expression levels of the gene of interest, 
the size of the plasmids, and replication efficiency of 
plasmids. The data also show that analysis of the plasmid 
retention in the total population confirms the essentiality 
of NMT sufficiently and the subsequent dissection of the 
respective retention is not necessary.
Conclusions
Taken together, the results support that NMT is essen-
tial in vivo. As demonstrated here and in the absence of 
a robust inducible expression system, plasmid shuffle 
is a useful and powerful tool to validate the essentiality 
of a gene of interest in an intracellular pathogen in vivo 
and hence robustly confirm its suitability as a therapeu-
tic target. This approach could also be used to charac-
terize a gene product both temporally and functionally 
in order to, e.g. determine whether an active phospho-
rylation site is required for establishment of infection or 
for longer-term intracellular survival, or to what extent 
protein domains are utilized in infective amastigotes as 
compared to vector-transmitted promastigotes of Leish-
mania. Overall, these in vitro and in vivo data are consist-
ent with the hypothesis that NMT is an essential gene for 
parasite viability and show, to our knowledge for the first 
time, that this target gene is not only essential in extracel-
lular promastigotes but also in the intracellular amastig-
otes of L. donovani, the causative agent of human visceral 
leishmaniasis.
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